Plain-English translation of NCT06912815 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether ustekinumab, a biologic medication that helps calm inflammation in Crohn's disease, works better when combined with a partial nutrition support plan to prepare patients for surgery. Currently, doctors use a strict nutrition-only approach before surgery. Researchers want to see if adding this medication while allowing patients to eat some regular food might be equally or more effective.
Before bowel surgery, Crohn's patients need to be in the best possible condition—both in terms of disease control and nutrition. While the new medication is approved for Crohn's disease, doctors don't yet know if combining it with a gentler eating plan might work as well as the current strict nutrition-only approach, which can be difficult for patients to follow.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication combined with a partial nutrition plan (where you eat some regular food plus nutrition supplements) or the standard full nutrition support approach (a strict liquid-only plan). You'll receive this treatment in the weeks before your scheduled surgery, with regular clinic visits to monitor how well the treatment is working and how you're feeling. Your surgery will go forward as planned once your doctor believes you're ready.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China